Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176787 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy With Capecitabine in Rectal Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00176787 is a Phase 2 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00176787, a Phase 2 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will use an experimental combination of treatment with the drug Capecitabine and radiation therapy prior to an operation for removal of the patient's tumor. The drug Capecitabine is an oral form of a drug called 5-FU which has been widely used to treat rectal cancer. This is a phase II clinical trial, which means that the physician will be studying the reactions of the patient's body and tumor to treatment with Capecitabine and radiation therapy. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. The study also will see what kind of side effects this experimental treatment causes and see how often these side effects occur. Preliminary human studies using Capecitabine and radiation therapy have produced encouraging results with acceptable side effects.
Interventions
- DRUG Capecitabine
- PROCEDURE Surgery
- PROCEDURE Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176787
The ClinicalTrials.gov registry entry for NCT00176787 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00176787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176787 about?
NCT00176787 is a clinical study titled "Radiation Therapy With Capecitabine in Rectal Cancer". This study will use an experimental combination of treatment with the drug Capecitabine and radiation therapy prior to an operation for removal of the patient's tumor. The drug Capecitabine is an oral form of a drug called 5-FU which has been widely used to treat rectal cancer. This is a phase II c...
What is the current status of trial NCT00176787?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2000-10. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00176787?
The interventions under investigation include: Capecitabine (DRUG), Surgery (PROCEDURE), Radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00176787?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.